Biotherapies in large vessel vasculitis

G. Pazzola; F. Muratore; N. Pipitone; C. Salvarani

doi:10.1016/j.revmed.2015.08.012

Biotherapies in large vessel vasculitis

G. Pazzola, F. Muratore, N. Pipitone, C. Salvarani

Arcispedale Santa Maria Nuova

Research output: Contribution to journal › Article › peer-review

Abstract

The mainstay of therapy of large vessel vasculitides (LVV) remains glucocorticoids (GC). Although most patients initially achieve disease remission, relapses and GC dependence are seen in more than two-thirds of cases. Conventional synthetic disease-modifying antirheumatic drugs (DMARDs) showed little or no steroid sparing effects, while biological agents represent a valid therapeutic option in patients with severe and/or relapsing LVV.

Original language	English
Pages (from-to)	274-278
Number of pages	5
Journal	Revue de Medecine Interne
Volume	37
Issue number	4
DOIs	https://doi.org/10.1016/j.revmed.2015.08.012
Publication status	Published - Apr 1 2016

Keywords

Biological therapies
Biotherapies
Giant cell arteritis
Large vessel vasculitis
Takayasu arteritis

ASJC Scopus subject areas

Gastroenterology
Internal Medicine

Access to Document

10.1016/j.revmed.2015.08.012

Cite this

@article{c346f04898f7413dad5ce621ca46a475,

title = "Biotherapies in large vessel vasculitis",

abstract = "The mainstay of therapy of large vessel vasculitides (LVV) remains glucocorticoids (GC). Although most patients initially achieve disease remission, relapses and GC dependence are seen in more than two-thirds of cases. Conventional synthetic disease-modifying antirheumatic drugs (DMARDs) showed little or no steroid sparing effects, while biological agents represent a valid therapeutic option in patients with severe and/or relapsing LVV.",

keywords = "Biological therapies, Biotherapies, Giant cell arteritis, Large vessel vasculitis, Takayasu arteritis",

author = "G. Pazzola and F. Muratore and N. Pipitone and C. Salvarani",

year = "2016",

month = apr,

day = "1",

doi = "10.1016/j.revmed.2015.08.012",

language = "English",

volume = "37",

pages = "274--278",

journal = "Revue de Medecine Interne",

issn = "0248-8663",

publisher = "Elsevier Masson",

number = "4",

}

TY - JOUR

T1 - Biotherapies in large vessel vasculitis

AU - Pazzola, G.

AU - Muratore, F.

AU - Pipitone, N.

AU - Salvarani, C.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The mainstay of therapy of large vessel vasculitides (LVV) remains glucocorticoids (GC). Although most patients initially achieve disease remission, relapses and GC dependence are seen in more than two-thirds of cases. Conventional synthetic disease-modifying antirheumatic drugs (DMARDs) showed little or no steroid sparing effects, while biological agents represent a valid therapeutic option in patients with severe and/or relapsing LVV.

AB - The mainstay of therapy of large vessel vasculitides (LVV) remains glucocorticoids (GC). Although most patients initially achieve disease remission, relapses and GC dependence are seen in more than two-thirds of cases. Conventional synthetic disease-modifying antirheumatic drugs (DMARDs) showed little or no steroid sparing effects, while biological agents represent a valid therapeutic option in patients with severe and/or relapsing LVV.

KW - Biological therapies

KW - Biotherapies

KW - Giant cell arteritis

KW - Large vessel vasculitis

KW - Takayasu arteritis

UR - http://www.scopus.com/inward/record.url?scp=84961204983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961204983&partnerID=8YFLogxK

U2 - 10.1016/j.revmed.2015.08.012

DO - 10.1016/j.revmed.2015.08.012

M3 - Article

AN - SCOPUS:84961204983

SN - 0248-8663

VL - 37

SP - 274

EP - 278

JO - Revue de Medecine Interne

JF - Revue de Medecine Interne

IS - 4

ER -

Biotherapies in large vessel vasculitis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this